Viveve Announces Presentation at World Meeting in Paris
SUNNYVALE, CA -- (Marketwired) -- 12/03/14 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced that Dr. Michael Krychman, a medical advisor to the company, a world renowned specialist in sexual health and the Executive Director of The Southern California Center for Sexual Health and Survivorship, will present the Viveve® System as a non-invasive treatment for vaginal introital laxity to improve sexual function in adult females during the 20th World Congress in Obstetrics, Gynecology & Infertility, being held December 4th through the 7th in Paris.
The presentation will highlight the results of two clinical studies in which the Viveve System was used to treat vaginal laxity, resulting from the over-stretching of vaginal tissue during childbirth. The Viveve Treatment works by remodeling collagen and restoring the tissue in the vaginal introitus. The studies, conducted in the United States and Japan, demonstrated that the 30-minute, outpatient procedure resulted in a statistically significant improvement in vaginal laxity and sexual satisfaction.
The pooled results from the two clinical studies indicate that at twelve months 88% of the women that participated in the study reported increased vaginal tightness, and women experienced a statistically significant 68% mean improvement in their vaginal laxity scores. No serious adverse events were reported in either study.
The presentation will also describe a pending randomized, sham-controlled, blinded clinical study with sites in Europe and Canada.
According to Dr. Krychman, "Physiological changes, like loss of vaginal introital integrity, are important contributing facets to female sexual function. The results of these studies show that patients demonstrated significant improvement in sexual function and fast recovery periods after treatment with the Viveve System. The Viveve Treatment has been shown to decrease sexual distress, improve vaginal introital integrity, and has been demonstrated to improve overall sexual satisfaction. The Viveve Treatment allows doctors to address a condition that I believe can profoundly impact a woman's quality of life."
"This presentation highlights the unique capabilities of the Viveve System," said Patricia Scheller, CEO of Viveve. "It is the only treatment for vaginal introital laxity that is simple, does not require anesthesia or analgesics, and for which there are no post-operative patient restrictions or lengthy recovery times."
Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten the tissues of the vaginal introitus (opening) and requires only a 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward looking statements". While management has based any forward looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports and registration statements available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Amato and Partners, LLC
Source: Viveve Medical, Inc.
Released December 3, 2014